August 29, 2024Interim Report for January-June 2024
May 30, 2024Interim Report for January-March 2024
February 29, 2024Year-end report for 2023
February 29, 2024Annual Review 2023
February 29, 2024Financial Statements 2023 (Finnish)
January 26, 2024Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
January 9, 2024Nanoform Management Presentation - SEB Nordic Seminar Copenhagen
December 14, 2023DNB Nordic Healthcare Conference
November 29, 2023Carnegie Finnish Healthcare Seminar
November 23, 2023SEB Annual Healthcare Seminar
November 22, 2023Interim Report for January-September 2023
August 24, 2023Interim Report for January-June 2023
July 4, 2023Nanoforming - the Patient- and Planet-Centric Approach From Increasing Bioavailability to Enabling Sustained Drug Delivery
May 25, 2023Interim Report for January-March 2023
February 28, 2023Year-end report for 2022
February 28, 2023Annual Review 2022
February 28, 2023Financial Statements 2022 (Finnish)
January 9, 2023SEB Nordic Seminar in Copenhagen
November 29, 2022Interim Report for January-September 2022
October 25, 2022Nanoform and TargTex – How drug delivery is enabling a clinical trial for Glioblastoma
August 25, 2022Interim Report for January-June 2022
May 24, 2022Interim Report for January-March 2022
February 22, 2022Year-end report for 2021
February 22, 2022Financial Statements 2021 (Finnish)
February 22, 2022Annual Review 2021
November 25, 2021Interim Report for January-September 2021
August 26, 2021Interim Report for January-June 2021
June 4, 2021Capital Markets Day 2021
May 27, 2021Interim Report for January-March 2021
February 26, 2021Annual Review 2020
February 26, 2021Year-end report for 2020
February 26, 2021Financial Statements 2020 (Finnish)
November 27, 2020Interim Report for January-September 2020
August 28, 2020Half-year Financial Report for January-June 2020
March 17, 2020Financial Statements 2019 (Approved by AGM 2020) - English
March 17, 2020Vuosikertomus 2019 (Yhtiökokouksen 2020 hyväksymä)
Questions from investors, analysts and journalists